You don't need to be signed in to read BMJ Blogs, but you can register here to receive updates about other BMJ products and services via our site.

Frontline IBD

‘Frontline IBD: Nutrition in IBD – what to do in theory and practice’

22 Mar, 16 | by Dr Philip J Smith, Frontline Gastroenterology Trainee Editor

After the great #FGDebate with the Dr Johnson, we are delighted to announce our next #FGDebate will be on Tuesday 22nd March 2016 with Dr Richard Hansen, Consultant Paediatric Gastroenterologist and Ms Joan Gavin, Paediatric Gastroenterology Dietician, at 8-9pm GMT and will discuss, ‘Frontline IBD: Nutrition in IBD – what to do in theory and practice’.

Dr Richard Hansen is a Consultant Paediatric Gastroenterologist at the new Glasgow Children’s Hospital. His main clinical interests are in inflammatory bowel disease, Helicobacter pylori and paediatric liver disease. He completed a PhD in gastrointestinal microbiology in 2012 and has published widely in this field. His ongoing research focuses on microbial therapeutic approaches to managing inflammatory bowel disease, including projects looking at nutrition, probiotics and faecal transplantation. Dr Hansen has been an early advocate of Twitter for free open access medical education (#FOAMED) and currently runs the twitter feed for British Society of Gastroenterology, Hepatology and Nutrition (@BSPGHAN), including the live tweeting of key conferences

Dr Richard Hansen

Dr Richard Hansen

 

Ms Joan Gavin is a Paediatric Gastroenterology Dietitian at Southampton Children’s Hospital. Her main interests are inflammatory bowel disease and gut allergy/intolerance. She has completed a masters degree on gastrointestinal malabsorption and has published work on nutritional intakes in inflammatory bowel disease. Joan recently presented data on maintenance nutrition in inflammatory bowel disease highlighting it’s role in prolonging remission at the BSPGHAN conference in January this year.

Ms Joan Gavin

Ms Joan Gavin

 

The #FGDebate will be a practical discussion about how to approach Nutrition in IBD from a theoretical and practical point of view.  We hope you can join us then using #FGDebate

 

Missed the #FGDebate with Ms Kay Greveson? Catch up with the Podcast and Storify summary of the debate here – ‘Frontline IBD: Travel and IBD – advice from the IBD Passport’

21 Feb, 16 | by Dr Philip J Smith, Frontline Gastroenterology Trainee Editor

If you missed the #FGDebate with Ms Kay Greveson, ‘Frontline IBD: Travel and IBD – advice from the IBD Passport’ you can catch up with the Storify summary of the #FGDebate at:

https://storify.com/FrontGastro_BMJ/frontline-ibd-travel-and-ibd-advice-from-ibd-passp

The podcast with Ms Kay Greveson can be listened to here:

Don’t forget to join us for the next #FGDebate which is with Dr Gavin Johnson (@drgavinoz) on Tuesday 23rd February 2016, at 8-9pm GMT and will discuss, ‘Frontline Training: The shape of gastroenterology training in the UK and beyond’

Slide1

‘Frontline IBD: Travel and IBD – advice from IBD Passport’

19 Jan, 16 | by Dr Philip J Smith, Frontline Gastroenterology Trainee Editor

After the great #FGDebate with the Dr Anton Emmanuel, we are delighted to announce our next #FGDebate will be on Tuesday 19th January 2016 with Ms Kay Greveson, IBD Nurse Specialist at the Royal Free Hospital, London, at 8-9pm GMT and will discuss, ‘Frontline IBD: Travel and IBD – advice from IBD Passport’.

Kay Greveson RGN, MSc, a qualified independent nurse prescriber, now works as lead IBD nurse at the Royal Free Hospital, London. She trained at Sheffield Teaching Hospitals NHS Foundation Trust where she was appointed an IBD specialist nurse. Her research interests include in travel health and IBD, transitional care and screening prior to Anti-TNF therapy. A speaker at national and international events, she has written for numerous journals and co-authored a chapter for ‘IBD Nursing’. She is involved in IBD-related projects for NICE and in Europe, and is a committee or faculty member of organisations including the European Crohn’s and Colitis Organisation.

 

Ms Kay Greveson

Ms Kay Greveson

During the #FGDebate Ms Greveson will cover:

  • Introduction to IBD Passport travel website
  • Pre-travel preparation
  • Vaccinations
  • Managing IBD overseas inc. Diet, medication, post-surgery and flare

Join us on Tuesday 19th January 2016 8-9pm GMT for the #FGDebate

Slide1

Missed the DDW Special #FGDebate with Professor Edward Loftus? Catch up with the Podcast and Storify summary of the debate here – ‘Frontline IBD: Hot topics in IBD’

4 Jun, 15 | by Dr Philip J Smith, Frontline Gastroenterology Trainee Editor

If you missed the DDW Special #FGDebate with Professor Edward Loftus on ‘Frontline IBD: Hot topics in IBD,’ you can catch up with the:

 

Podcast after the #FGDebate at

 

https://soundcloud.com/bmjpodcasts/frontline-ibd-hot-topics

 

Or the Storify summary of the #FGDebate at

 

https://storify.com/FrontGastro_BMJ/frontline-ibd-hot-topics-in-ibd

 

Don’t forget to join us for the next debate which is with Professor Andres Cardenas (@acv69cardenas), Associate Editor of Frontline Gastroenterology and Professor of Hepatology at the GI Unit, University of Barcelona on Tuesday 9th June 2015, at 8-9pm GMT and will discuss, ‘Frontline Hepatology: Complications with cirrhosis – portal hypertension’.

 

FGDebate June 2015

‘Frontline IBD: Hot topics in IBD’

10 May, 15 | by Dr Philip J Smith, Frontline Gastroenterology Trainee Editor

After the great success of the #FGDebate with Dr Simon Gabe, we are delighted to announce our next #FGDebate will be a #DDW15 Special debate with world renowned IBD expert Professor Edward Loftus (@EdwardLoftus2), Professor of Gastroenterology and IBD, Mayo Clinic, Rochester, Minnesota, USA, on Monday 11th May 2015, at 9-10pm GMT and will discuss, ‘Frontline IBD: Hot topics of IBD’.FG Twitter E-Card May 2015 (2)

Dr. Loftus is a Professor of Medicine and Director of the Inflammatory Bowel Disease Interest Group, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Edward V. Loftus, Jr. earned a medical degree at the University of Pennsylvania and completed a residency in internal medicine at Temple University Health Sciences Center in Philadelphia. He served one year as a general medical officer in the Indian Health Service at Fort Belknap P.H.S. Indian Hospital in Harlem, Montana, and then completed a fellowship in gastroenterology at the Mayo Graduate School of Medicine. He has been on the Mayo Clinic consulting staff since 1995.

Dr. Loftus is a Fellow of the American College of Physicians (ACP), the American College of Gastroenterology (ACG), and the American Gastroenterological Association (AGA). He is a member of several professional societies, including the ACP, AGA, ACG, American Society for Gastrointestinal Endoscopy, and the Crohn’s & Colitis Foundation of America (CCFA). He served as Chair of the Patient Education Committee of the CCFA from 2002 to 2005. He has served on several ACG committees, and has been an abstract reviewer for both AGA and ACG for a number of years. He is currently the Chair of the Immunology, Microbiology, and Inflammatory Bowel Disease section of the AGA Institute Council.

Professor Edward Loftus

Professor Edward Loftus

Among Dr. Loftus’ awards are the Mayo Department of Medicine Laureate Award (2007) and the CCFA, Minnesota – Dakotas Chapter, Physician of the Year Award (2008). He was elected to membership in the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) in 2008. Dr Loftus was named Teacher of the Year by the Mayo gastroenterology fellows in 2010-11. He has been named to the list of Best Doctors in America since 2005 and to Castle Connolly’s Top Doctors in America list since 2010.

He served as Associate Editor of the American Journal of Gastroenterology between 2003 and 2009, and as Associate Editor of Inflammatory Bowel Diseases from 2006 to 2013.

Dr. Loftus has published over 270 original articles, book chapters, or editorials and more than 300 abstracts, and has lectured extensively on the epidemiology, natural history, diagnosis, and medical management of inflammatory bowel diseases. Dr. Loftus has served as the principal investigator on several funded studies focusing on the epidemiology and natural history of inflammatory bowel disease.

In advance of the #FGDebate, Professor Edward Loftus says:

“To (badly) paraphrase a certain 19th century English author, now is the “best of times” and “worst of times” in the field of inflammatory bowel disease (IBD). While it has been an “age of wisdom”, it has also been an “age of foolishness.” Huge advances have been made in understanding aspects of IBD pathogenesis (think genetics, immunology, microbiome, etc.), but we are still frustratingly far from understanding enough to result in a cure for IBD. In the United States, there are now six biologic agents commercially available for the treatment of Crohn’s disease or ulcerative colitis, and, over the next 3 to 5 years, we could very well see approval for several more effective therapeutic agents. Several jurisdictions in Europe have seen the advent of a biosimilar for infliximab, which ultimately could result in cost savings and perhaps improved access to biologics. Yet, at the same time, we are just scratching the surface in understanding how to properly use individual medications and combinations of medications to not only make our patients feel better, but also to achieve disease modification, or alteration in the natural history of these diseases. Later this week, thousands of physicians and scientists will be streaming into Washington, D.C., for Digestive Disease Week 2015, where we’ll hear about cutting edge science and medicine related to gastroenterology. Over 1,000 abstracts were submitted to the IBD section of the American Gastroenterological Association meeting during DDW.

In tomorrow’s Frontline Gastroenterology Debate, I hope to be able to highlight some of the advances which have been made in recent years to manage patients with IBD. Since Dr. Charlie Lees did such a nice job reviewing issues related to pathogenesis of IBD in his October 2014 #FGDebate, much of my focus will be on advances in clinical management, such as risk stratification, earlier intervention in the disease course with effective therapies, objective assessment of inflammation to make treatment decisions, early reassessment of changes in therapy to determine if the change has been successful (“treat to target”), and therapeutic drug monitoring. However, I am happy to take any questions related to the field of IBD. Looking forward to this interaction on social media!”

Join us on Monday 11th May 2015, 9-10pm GMT for the #FGDebate!

 

Missed the #FGDebate with Dr Charlie Lees? Catch up with the Podcast and Storify summary of the debate – ‘Frontline IBD: Finding the cause of IBD – genes, bugs or diet?’

21 Oct, 14 | by Dr Philip J Smith, Frontline Gastroenterology Trainee Editor

If you missed the #FGDebate with Dr Charlie Lees, ‘Frontline IBD: Finding the cause of IBD – genes, bugs or diet?’, you can catch up with the:

Podcast with Dr Lees, after the #FGDebate: https://soundcloud.com/bmjpodcasts/finding-the-cause-of-ibd-genes-bugs-or-diet/s-GTLBB

or the Storify summary of the #FGDebate at:https://storify.com/FrontGastro_BMJ/frontline-ibd-finding-the-cause-of-ibd-genes-bugs

Don’t forget to join us for the next debate with Prof Sir Ian Gilmore!

FG-Twitter-E-Card-Nov2014

 

 

 

 

 

Frontline IBD: Finding the cause of IBD – genes, bugs or diet? #FGDebate

2 Oct, 14 | by Dr Philip J Smith, Frontline Gastroenterology Trainee Editor

After the great success of our first ever #FGDebate we are delighted to announce our second debate will be lead by Dr Charlie Lees (@charlie_lees), Consultant Gastroenterologist and IBD Specialist, on 14th OCtober 2014, at 8-9pm GMT and discuss, “‘Frontline IBD: Finding the cause of IBD – genes, bugs or diet?”

Dr Charlie Lees is a consultant gastroenterologist at the Western General Hospital, Edinburgh and honorary senior lecturer at the University of Edinburgh. He trained at University College London and subsequently in Edinburgh, with doctoral studies in the Satsangi lab.

Dr Charlie Lees

 

He was awarded the prestigious ASNEMGE (now UEG) European Rising Star in Gastroenterology Award in 2009. His major clinical, research and teaching interest is inflammatory bowel disease. He was a committee member of EduCom at ECCO from 2009-2013, and is presently chairing the SSG IBD Interest Group and sitting on the BSG IBD Research Committee. His major research activities are at the translational interface between basic science and direct clinical application. These include the genetics and pharmacogenetics of IBD (member of Wellcome Trust Case Control Consortium, UKIBDGC and IIBDGC management committee), the role of diet, nutrition and the gut microbiota in disease aetiopathogenesis and prognosis, IBD therapeutics, monitoring and e-health. He is chief investigator of the UK-arm of the important GEM study (www.gemproject.ca), a $20m cohort study investigating the underlying cause of Crohn’s disease, and also of the pan-UK PREdiCCt study (launching 2015). Major international teaching activities include directing the ECCO Advanced IBD Course, the ECCO-CIMF Chinese Masterclass in IBD, the United European Gastroenterology (UEG) Summer School and Young Investigators Programme, and the Wellcome Trust Advanced Course in Genomic Medicine for Clinicians.

In advance of that #FGDebate, Dr Lees says:

‘The inflammatory bowel diseases, Crohn’s disease and ulcerative colitis, are common in the Western world affecting about 1 in 200 individuals. In recent years incidence has increased dramatically in developing countries in parallel with the adoption of a Western lifestyle. Whilst the precise aetiology of IBD remains illusive the currently held paradigm is of dysregulated immune responses to commensal gut bacteria in genetically susceptible individuals. Gene discovery in IBD has seen unparalleled success in complex diseases. Nearly 200 disease genes have been identified. These findings have started to yield fruit with important insights into disease biology. However they also demonstrate the underlying complexity of disease pathogenesis. Furthermore, they only appear to explain around one quarter of phenotypic variance – ie why an individual develops disease. Much attention has now start to focus on the role of the gut microbiota in IBD. There is clearly reduced microbial diversity in IBD patients, but it remains unknown which critical aspects of the observed dysbiosis are potentially causal or simply the effect of underlying inflammation. Moreover, the interplay between environmental factors, notably antibiotic exposure and habitual diet, underlying genetic variation and the gut microbiota are only just starting to be explored.

 

Twitter debate _ figure 1

 

In this Frontline Gastroenterology twitter debate we will explore these issues and discuss how present data, planned and future studies can / should address this critical question. How will we find out what causes IBD to develop? Will this knowledge help us prevent the disease from developing in high-risk individuals? Are the environmental triggers for disease onset the same as those for disease flare in patients with established disease? Will these findings bring us closer to a ‘cure’ or at least prolonged remission in those with established disease?

Join us on Tuesday 14th October to tackle these important issues and bring other questions and ideas to the discussion.’

We look forward to you joining us then for the second #FGDebate

FG-Twitter-Card_Oct_2014

Frontline Gastroenterology Blog homepage

Frontline Gastroenterology

Frontline Gastroenterology aims to accelerate the adoption of best practice in the fields of gastroenterology and Hepatology; focusing on the needs of patients and the professionals caring for them.Visit site



Creative Comms logo